Comella Named One of the 50 Most Influential People in Stem Cells

Share Article

Regenerative Medicine Institute, Mexico Advisory Board Member Honored

“Our board certified physicians have been able to utilize the work of stem cells leaders like Kristin in order to treat chronic degenerative diseases,” Lopez said.

Kristin Comella, a member of the Regenerative Medicine Institute, Mexico (RMI) Scientific Advisory Board, has been named one of the 50 most influential people in stem cells today.

The World Stem Cells Regenerative Medicine Congress of 2013 recognized Comella for her multiple career achievements. The Congress included Comella due to her expertise in regenerative medicine, training and education, research, product development, and senior management. With more than 12 years of cell culturing experience, Comella’s career has included developing stem cell therapies for osteoarthritis and managing the stem cell laboratory at Tulane University’s Center for Gene Therapy.

“It is Kristin’s understanding of the function of adult stem cells and her constant improvement of techniques to yield higher quality and quantity of stem cells that make her a natural leader in the field,” said Dr. Javier Lopez, President and CEO of RMI.

As part of Bioheart, Inc. leadership in 2010 Comella was instrumental in establishing a working agreement between Bioheart and RMI. She has worked directly with RMI physicians to develop more than 20 clinical trial protocols, is involved with auditing RMI lab results, and is head of one of the three organizations responsible for evaluating trial data.

“Our board certified physicians have been able to utilize the work of stem cells leaders like Kristin in order to treat chronic degenerative diseases,” Lopez said. “The use of microcatheters is one the reason RMI’s protocols have delivered promising results in this new and exciting field.”

Due to the relationship established between RMI and Bioheart, RMI has been accepted as a clinical site for Bioheart’s ANGEL Trial. This Phase 1 study is designed to determine the safety and effects of adipose derived stem cells in patients with chronic heart ischemia. RMI has treated more than 100 patients. Conditions treated include chronic heart failure, COPD, lower limb ischemia, osteoarthritis, and other chronic diseases.

For more information, visit regenerativemedicine.mx.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website